Table 3.

Follow–up changes in echocardiography in the original cohort.

	ARNI group				ACEi/ARB group
Parameter	Valid N	Baseline	Follow–up	Variation (%)	Valid N	Baseline	Follow–up	Variation (%)	P-value†
LVEF%	105	29.1 ± 6.6	37.4 ± 14.7*	8.3 ± 14.6	467	31.7 ± 7.1	42.5 ± 15.7*	10.8 ± 15.2	0.228
LVEDD mm	106	60.5 ± 9.2	57.3 ± 8.6*	−3.1 ± 7.8	467	56.7 ± 9.0	55.7 ± 8.9*	−1.0 ± 6.1	0.013
LVESD mm	106	51.0 ± 8.7	46.3 ± 10.3*	−4.7 ± 9.7	467	45.3 ± 10.2	43.2 ± 10.7*	−2.1 ± 8.1	0.017
LA mm	107	45.3 ± 8.2	44.5 ± 7.8	−0.8 ± 7.8	469	43.8 ± 7.2	43.5 ± 8.1	−0.2 ± 6.2	0.456
	Valid N	Baseline	12 months	P -value	Valid N	Baseline	12 months	P -value
Severe MR	111	13 (13.7%)	7 (7.4%)	0.058	492	25 (7.3%)	25 (7.3%)	1.000	0.079

ARNI, angiotensin receptor–neprilysin inhibitor; ACEi, angiotensin–converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF, center ventricular ejection fraction; LVEDD, center ventricular end–diastolic dimension; LVESD, center ventricular end–systolic diameter; LA, center atrium; MR, mitral regurgitation.

^* P < 0.05 vs. the baseline value;

^†The difference in the change between the ARNI and ACEi/ARB groups.